Condition focus: Dry Eye Disease & Ocular Surface Inflammation:
Light-emitting diode (LED)-based photobiomodulation (PBM) has been used to treat many inflammatory diseases, including neurological and dermatological conditions; several researchers are exploring PBM in an ophthalmological context. PBM phototherapy uses visible and near-infrared (NIR) light to control pain and inflammation without any complications, aiding immune system regulation, tissue production, wound healing, and neurogenesis. In particular, red LED light with a wavelength of 600–700 nm enhances the immune response and cell proliferation, and NIR LED light with a wavelength 800 nm exerts anti-inflammatory effects. Several studies reported that PBM effectively improved the tear breakup time and tear volume and reduced the inflammatory response. Several clinical studies have explored the effects of LED light on the ocular surfaces of dry eye patients; the treatment was useful, but the parameters studied varied. Although single-wavelength LEDs have been extensively studied, multi-wavelength LEDs have not. Therefore, we evaluated the in vivo effects of simultaneous 680, 780, and 830 nm LED light treatments.
WaveFront Alignment: The Spectral WaveFront uses 670 nm and 810 nm in an ocular-specific delivery geometry that overlaps with the mitochondrial and inflammatory pathways described in Goo et al. While the study employed a three-wavelength array, the observed improvements in tear-film stability, epithelial protection, and inflammatory reduction are directionally consistent with PBM at 670/810 nm.
More information here
Editor’s note: Goo et al. 2023 provide foundational mechanistic insight into red and near-infrared LED PBM for ocular-surface inflammation. For comparison with WaveFront wavelength selection and energy windows, see our WaveFront Evidence Alignment. Related PBM clinical dry eye outcomes can be found in Park 2022 and Antwi 2024. For earlier mitochondrial and oxidative-stress mechanisms relevant to PBM, see Begum 2013.
